Engineered oncolytic viruses expressing PD-L1 inhibitors have clinical potentials for curing cancers resistant to PD-1/PD-L1 ICI, as they are able to activate tumor neoantigen–specific T-cell responses (185). Here, CD274 is linked to cancer.